US OptionsDetailed Quotes
NVAX250509P9500
- 2.13
- 0.000.00%
15min DelayClose May 5 16:00 ET
0.00High0.00Low
2.13Open2.13Pre Close0 Volume1 Open Interest9.50Strike Price0.00Turnover227.95%IV-17.54%PremiumMay 9, 2025Expiry Date3.23Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9576Delta0.0651Gamma1.93Leverage Ratio-0.0137Theta-0.0007Rho-1.85Eff Leverage0.0006Vega
Novavax Stock Discussion
Novavax Strengthens Japan Presence: Improved Financial Terms in Takeda Partnership Boost COVID Vaccine Distribution
Novavax () issued the following update on the U.S. FDA BLA for Novavax’s COVID-19 Vaccine: “Last week, Novavax responded to the formal communication received from the U.S. Food and Drug Administration for our Biologics License Application (BLA) and our response addresses the request for a postmarketing commitment for a clinical trial. PMCs by their nature are completed after BLA approval. PMCs are not unusual with many approved drugs and/or biologics having at least one PMC or...
Good loading level.
Full FDA Approval: 10-30
Pandemic: 150-250
Whoever decided to sell at 7+ dollars, you are either crazy or just here for trade with quick profit. This ain’t some penny stock we are talking about. Hold well and you will be rewarded handsomely.
The $Nasdaq Composite Index (.IXIC.US)$ led the way higher, gaining 407.63 (2.5%) to 16,708.05, while the $S&P 500 Index (.SPX.US)$ added 88.10 ticks (1.7%) to 5,375.86.
Similarly, the $Dow Jones Industrial Average (.DJI.US)$ rose 419....
as a long term investor, this is nothing compare to the official approval, and the jackpot, next pandemic.
Novavax: "We Believe That Our Bla Is Approvable Based on Conversations With FDA, as of Our Pdufa Date on April 1 and Through Today
Bank of America believe it’s valued at 10 dollars.
New Study Reveals Novavax COVID Vaccine Cuts Side Effects Nearly in Half vs Pfizer
No comment yet